Differences in Smad4 expression in human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck squamous cell carcinoma

Clinical Cancer Research

Volumn 11, Issue 9, 2005, Pages 3191-3197

  Báez, Adriana ^a   Cantor, Alan ^b   Fonseca, Sharon ^a   Marcos Martinez, Maria ^a   Mathews, Linda A ^b   Muro Cacho, Carlos A ^b   Muñoz Antonia, Teresita ^b  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; ESOPHAGUS CANCER; FEMALE; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RISK FACTOR; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DNA, VIRAL; DNA-BINDING PROTEINS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 18244404839     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1299     Document Type: Article

References (58)

1. Massague J. TGF-β signal transduction. Annu Rev Biochem 1998;67:753-91.
2. Massague J, Attisano L, Wrana JL. The TGF-β family and its composite receptors. Trends Cell Biol 1994;4: 172-8.
3. Alexandrow MG, Moses HL. Transforming growth factor β and cell cycle regulation. Cancer Res 1995; 55:1452-7.
4. Attisano L, Wrana JL. Smads as transcriptional comodulatots. Curr Opin Cell Biol 2000;12:235-43.
5. Garrigue-Antar L, Muñoz-Antonia T, Antonia SJ, Gesmonde J, VelLucci VF. Missense mutations of the transforming growth factor β type II receptor in human head and neck squamous carcinoma cells. Cancer Res 1995;55:3982-7.
6. Eisma RJ, Spiro JD, von Biberstein SE, Lindquist R, Kreutzer DL. Decreased expression of transforming growth factor β receptors on head and neck squamous cell carcinoma tumor cells. Am J Surg 1996; 172:641-5.
7. Muñoz-Antonia T, Li XC, Reiss M, Antonia SJ. A mutation in the TGF-β receptor gene promoter associated with loss of gene expression. Cancer Res 1996;56: 4831-5.
8. Muro-Cacho CA, Anderson M, Cordero J, Muñoz-Antonia T. Expression of transforming growth factor β type II receptors in head and neck squamous cell carcinoma. Clin Cancer Res 1999;5:1243-8.
9. Muro-Cacho C, Rosario-Ortiz K, Livingston S, Muñoz-Antonia T. Defective transforming growth factor β signaling pathway in head and neck squamous cell carcinoma is evidenced by the lack of expression of activated Smad2. Clin Cancer Res 2001; 7:1618-26.
10. Logullo AF, Nonogaki S, Miguel RE, et al. Transforming growth factor β1 (TGFβ1) expression in head and neck squamous cell carcinoma patients as related to prognosis. J Oral Pathol Med 2003;32:139-45.
11. Chen T, Yan W, Wells RG, et al. Novel inactivating mutations of transforming growth factor-β type I receptor gene in head-and-neck cancer metastases. Int J Cancer 2001;93:653-61.
12. Knobloch TJ, Lynch MA, Song H, et al. Analysis of TGF-β type I receptor for mutations and polymorphisms in head and neck cancers. Mutat Res 2001; 479:131-9.
13. Kim SJ, Im YH, Markowitz SD, Bang YJ. Molecular mechanisms of inactivation of TGF-β receptors during carcinogenesis. Cytokine Growth Factor Rev 2000; 11:159-68.
14. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-3.
15. Suto T, Sugai T, Habano W, et al. Allelotype analysis of the PTEN, Smad4 and DCC genes in biliary tract cancer. Anticancer Res 2002;22:1529-36.
16. Iacobuzio-Donahue CA, Song J, Parmiagiani G, Yeo CJ, Hruban RH, Kern SE. Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors. Clin Cancer Res 2004;10:1597-604.
17. Takagi Y, Kohmura H, Futamara M, et al. Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. Gastroenterology 1996;111:369-72.
18. Fukushima T, Mashiko M, Takita K, et al. Mutational analysis of TGF-β type II receptor, Smad2, Smad3, Smad4, Smad6 and Smad7 genes in colorectal cancer. J Exp Clin Cancer Res 2003;22:315-20.
19. Blaker H, von Herbay A, Penzel R, Gross S, Otto HF. Genetics of adenocarcinomas of the small intestine: frequent deletions at chromosome 18q and mutations of the SMAD4 gene. Oncogene 2002;21:158-64.
20. Natsugoe S, Xiangming C, Matsumoto M, et al. Smad4 and transforming growth factor β 1 expression in patients with squamous cell carcinoma of the esophagus. Clin Cancer Res 2002;8: 1838-42.
21. Eppert K, Scherer SW, Ozcelik H, et al. MADR2 maps to 18q21 and encodes a TGFβ regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996;86:543-52.
22. Maliekal TT, Antony ML, Nair A, Paulmurugan R, Karunagaran D. Loss of expression, and mutations of Smad2 and Smad4 in human cervical cancer. Oncogene 2003;22:4889-97.
23. Boulay JL, Mild G, Lowy A, et al. SMAD7 is a prognostic marker in patients with colorectal cancer. Int J Cancer 2003;104:446-9.
24. Xu G, Chakraborty C, Lala PK. Expression of TGF-β signaling genes in the normal, premalignant, and malignant human trophoblast: loss of smad3 in chorio-carcinoma cells. Biochem Biophys Res Commun 2001; 287:47-55.
25. Lee DK, Kim BC, Kim IY, Cho EA, Satterwhite DJ, Kim SJ. The human papillomavirus E7 oncoprotein inhibits transforming growth factor-β signaling by blocking binding of the Smad complex to its target sequence. J Biol Chem 2002;277:38557-64.
26. Lee DK, Kim BC, Brady JN, Jeang KT, Kim SJ. Human T-cell lymphotropic virus type 1 tax inhibits transforming growth factor-β signaling by blocking the association of Smad proteins with Smad-binding element. J Biol Chem 2002;277:33766-75.
27. Saha D, Datta PK, Beauchamp RD. Oncogenic ras represses transforming growth factor-β/Smad signaling by degrading tumor suppressor Smad4. J Biol Chem 2001;276:29531-7.
28. Pirisi L, Creek KE, Doniger J, DiPaolo JA. Continuous cell lines with altered growth and differentiation properties originate after transfection of human keratinocytes with human papillomavirus type 16 DNA. Carcinogenesis 1988;9:1573-9.
29. zur Hausen H. Papillomavirus infections: a major cause of human cancers. Biochim Biophys Acta 1996; 1288:F55-78.
30. Brandsma JL, Abramson AL. Association of papillomaviruses with cancers of the head and neck. Arch Otolaryngol Head Neck Surg 1989;115:621-62.
31. McKaig RG, Baric RS, Olshan AF. Human papillomavirus and head and neck cancer: epidemiology and molecular biology. Head Neck 1998;20:250-65.
32. Gillison ML, Koch WM, Capone RB, et al. Evidence for causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-20.
33. Dyson N, Howley PM, Münger K, Harlow E. The human papillomavirus 16 E7 protein is able to bind the retinoblastoma gene product. Science (Washington, DC) 1989;243:934-7.
34. Boyer SN, Wazer DE, Band V. E7 protein of human papillomavirus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996;56:4620-4.
35. Werness BC, Levine AJ, Howley PM. Association of human papilloma virus type 16 and 18 E6 proteins with p53. Science (Washington, DC) 1990;248: 76-9.
36. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993;75:495-505.
37. 2 checkpoint function in human fibroblasts expressing human papillomavirus type 16 E6 oncoprotein. Oncogene 1998;16:1825-38.
38. Hasskarl J, Butz K, Whitaker N, Ullmann A, Durst M, Hoppe-Seyler F. Differential cell cycle response of nontumorigenic and tumorigenic human papillomavirus-positive keratinocytes towards transforming growth factor-β1. J Mol Med 2000;78:94-101.
39. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000;92:690-8.
40. Creek KE, Geslani G, Batova A, Pirisi L. Progressive loss of sensitivity to growth control by retinoic acid and transforming growth factor-β at late stages of human papillomavirus type16-initiated transformation of human keratinocytes. Adv Exp Med Biol 1995;375:117-35.
41. Kang SH, Won K, Chung HW, et al. Genetic integrity of transforming growth factor β (TGF-β) receptors in cervical carcinoma cell lines: loss of growth sensitivity but conserved transcriptional response to TGF-β. Int J Cancer 1998;77:620-5.
42. Mi Y-d, Borger D, Fernandes PR, Pirisi L, Creek KE. Loss of transforming growth factor-β (TGF-β) receptor type1 mediates TGF-β resistance in human papillomaviruses type-16 transformed human keratinocytes at late stages of in vitro progression. Virology 2000; 270:408-16.
43. Chen T, deVries EG, Hollema H, et al. Structural alterations of transforming growth factor-β receptor genes in human cervical carcinoma. Int J Cancer 1999;82: 43-51.
44. Nees M, Geoghegan JM, Munson P, et al. Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-β2 in cervical keratinocytes. Cancer Res 2000;60:4289-98.
45. Rorke EA, Zhang D, Choo CK, Eckert RL, Jacobberger JW. TGF-β-mediated cell cycle arrest of HPV16-immortalized human ectocervical cells correlates with decreased E6/E7 mRNA and increased p53 and p21 (WAF-1) expression. Exp Cell Res 2000; 259:149-53.
46. Lee S, Cho YS, Shim C, et al. Aberrant expression of Smad4 results in resistance against the growth inhibitory effect of transforming growth factor β in the SiHa human cervical carcinoma cell line. Int J Cancer 2001; 94:500-7.
47. Spitz MR. Epidemiology and risk factors for head and neck cancer. Semin Oncol 1994;21:281-8.
48. Liu X, Han S, Baluda MA, Park NH. HPV16 oncogenes E6 and E7 are mutagenic in normal human oral keratinocytes. Oncogene 1997;4: 2347-52.
49. Báez A, Almodóvar JI, Cantor A, et al. High frequency of HPV16-associated head and necksquamous cell carcinoma in the Puerto Rican population. Head Neck 2004;26:778-84.
50. Fukuchi M, Masuda N, Miyazaki T, et al. Decreased Smad4 expression in transforming growth factor-β signaling pathway during progression of esophageal squamous cell carcinoma. Cancer 2002;737-43.
51. Takebayashi S, Igawa T, Jung KY, et al. Identification of new minimally lost regions on 18q in head and neck squamous cell carcinoma. Cancer Res 2000;60: 3397-403.
52. Nagatake M, Takagi Y, Osada H, et al. Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res 1996;56:2718-20.
53. Wang D, Kanuma T, Takama F, et al. Mutation analysis of the Smad3 gene in human ovarian cancers. Int J Oncol 1999;15:949-53.
54. Takakura S, Okamoto A, Saito M, et al. Allelic imbalance in chromosome band 18q21 and SMAD4 mutations in ovarian cancers. Genes Chromosomes Cancer 1999;24:264-71.
55. Riggins GJ, Kinzler KW, Vogelstein B, Thiagalingam S. Frequency of Smad gene mutations in human cancers. Cancer Res 1997;57:2578-80.
56. Kawate S, Takenoshita S, Ohwada S, et al. Mutation analysis of transforming growth factor β type II receptor, Smad2, and Smad4 in hepatocellular carcinoma. Int J Oncol 1999;14:127-31.
57. Latil A, Pesche S, Valri A, Fournier G, Cussenot O, Lidereau R. Expression and mutational analysis of the MADR2/smad2 gene in human prostate cancer. Prostate 1999;40:225-31.
58. Grau AM, Zhang L, Wang W, et al. Induction of p21waf expression and growth inhibition by transforming growth factor β involves the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res 1997;57: 3929-34.